Aurenar's core product, V-Link, is a simple, wireless, single-use transauricular vagus nerve stimulation device designed to modulate the body's inflammatory response in critically ill patients. The platform was developed from research at Washington University School of Medicine and has received FDA breakthrough device designation. Clinical work cited by the company includes a randomized subarachnoid hemorrhage (SAH) trial reporting a greater than 40% reduction in moderate-to-severe vasospasm, lowered pro-inflammatory cytokines, improved functional outcomes, and a companion analysis showing a 20% drop in 30-day modifiable hospitalization costs; a separate large-vessel occlusion (LVO) ischemic stroke trial reportedly showed consistent anti-inflammatory effects and a clean safety profile. V-Link's wireless design is intended to simplify use by neuro-intensive care physicians and ICU nursing staff to support faster onboarding and adoption. Headquartered in St. Louis, Aurenar plans to use its newly raised seed capital to complete device development, V&V testing, and regulatory submissions ahead of pivotal trials.

Total raised

$6M

Funding rounds

1

Latest round

Seed

Latest activity

Jul 2026